The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma ctDNA technologies in both commercial and academic laboratories are in routine or emerging use. The increasing integration of such testing to inform treatment decision making by oncology clinicians has complexities and challenges but holds significant potential to substantially improve patient outcomes. In this review, the authors discuss the current role of plasma ctDNA assays in oncology care and provide an overview of ongoing research that may inform real-world clinical applications in the near future.

中文翻译：

---

晚期实体瘤中循环肿瘤DNA：临床相关性和未来方向

使用血浆循环肿瘤 DNA (ctDNA) 进行基因组分析的应用在晚期实体瘤患者的管理中正在迅速发展。商业和学术实验室中的多种血浆 ctDNA 技术正处于常规或新兴应用中。越来越多地整合此类测试以告知肿瘤临床医生的治疗决策具有复杂性和挑战，但具有显着改善患者预后的巨大潜力。在这篇综述中，作者讨论了血浆 ctDNA 检测在肿瘤治疗中的当前作用，并概述了正在进行的研究，这些研究可能会在不久的将来为现实世界的临床应用提供信息。